Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome
Information Services, Academic Computing Services; Department of Cell Biology; Department of Pathology
Cancer Biology | Oncology | Pathology
Hypocellular myelodysplastic syndrome (MDS) represents only a small portion of MDS, of which, the clinical significance has not been well-defined. By using currently accepted age-adjusted criteria to define hypocellularity as 70 years old, we identified 163 (15.5%) hypocelluar MDS from 1049 consecutive adult MDS patients over an 11-year period (1995-2006). Compared to normal/hypercellular MDS, hypocellular MDS patients were younger (p<0.01), less anemic (p=0.02), but more neutropenic (p<0.001) and thrombocytopenic (p=0.05), and had a comparable cytogenetic risk group distribution (p=0.09) and international prognostic scores (IPSS, p=0.13). With a median follow-up of 52 months, hypocellular MDS showed a favorable overall survival (56 months versus 28 months, log-rank p<0.0001) over normal/hypocellular MDS, and this survival preference was also demonstrated in all IPSS groups and cytogenetic risk groups, and was independent of all other risk factors (Cox regression test, p=0.01). In conclusion, our study demonstrated that hypocellular MDS has characteristic clinicopathologic features, and bone marrow hypocellularity in MDS is an independent factor which predicts a favorable outcome.
DOI of Published Version
Leuk Res. 2008 Apr;32(4):553-8. Epub 2007 Sep 20. Link to article on publisher's site
Yue G, Hao S, Fadare O, Baker SP, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. (2007). Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Information Technology Publications. https://doi.org/10.1016/j.leukres.2007.08.006. Retrieved from https://escholarship.umassmed.edu/infoservices/68